If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen closely. In a new trial conducted by Eli Lilly, its tirzepatide injection for weight loss,

Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and Wegovy, to growing children

Last year’s study in the journal Obesity had revealed that of people prescribed weight-loss drugs, just 44 per cent were still taking them after three months and only 19 per cent after one year.

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

A rival drug company is celebrating results claiming its drug helps patients lose more weight than Novo Nordisk’s Wegovy. Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Wegovy in the first large,

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks.

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its latest trial comparing its medication,

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.